TriVerity™ is the first and only FDA-cleared molecular blood test that simultaneously identifies infection type (bacterial vs. viral) and assesses illness severity in ED patients with suspected acute infection or sepsis — from a single blood draw, in ~30 minutes.
When a patient arrives with a possible infection, traditional biomarkers like WBC, lactate, and procalcitonin weren't designed to simultaneously tell you infection type (bacterial vs viral) and illness severity — leaving clinicians to guess at the most consequential decision point in care.
01
Non-infectious conditions — inflammation, autoimmune, metabolic — can mimic infection. Traditional biomarkers can't reliably distinguish between them, driving false sepsis alerts and unnecessary sepsis bundle activations.
02
The answer determines whether antibiotics are needed — but blood cultures take 12–72 hours and often return negative. Physicians are forced to default to broad-spectrum antibiotics "just in case," driving overuse and resistance.
03
Some patients appear stable at presentation while they've already begun decompensating. Others aren't as sick as they appear. Without a severity signal, the safest decision defaults to admission — whether or not it's necessary.
TriVerity enables clinicians to make admit vs. discharge, patient disposition, and treatment decisions earlier — at the front end of care, when clinical and financial impact is greatest.
Deliver objective biological evidence that supports safe discharge decisions and reduces unnecessary admissions — without adding beds, staff, or infrastructure.
TriVerity's Illness severity scoring enables earlier recognition of high-risk patients who may not yet appear critically ill — so escalation happens when it can still make a difference.
Identify patients who truly need aggressive diagnostics while avoiding unnecessary testing, antibiotic overuse, and costly SEP-1 variability — backed by defensible, biologically grounded documentation.
Instead of looking for a specific pathogen or relying on traditional biomarkers, TriVerity reads the expression of 29 immune system mRNAs using AI/ML algorithms, giving clinicians a new capability to move from uncertainty-driven decisions to evidence-driven decisions at the very front end of care.
Published in Nature Medicine — SEPSIS-SHIELD is one of the most rigorous prospective validation studies for any acute infection diagnostic.
| Score | Sensitivity | Specificity |
|---|---|---|
| Bacterial | 97% | 95% |
| Viral | 95% | 98% |
| Severity | 93% | 99% |
The body signals infection through immune-response changes long before inflammation via biomarkers or pathogens via cultures become detectable. TriVerity reads those signals first.
TriVerity reads at the earliest signal
mRNA signals
in hours
Hours later,
non-specific
Later still,
imprecise
12–72 hrs,
if bacteremic
Time from infection onset
TriVerity's three independent scores create value across clinical, operational, and financial priorities simultaneously — without adding complexity to existing workflows.
Earlier, more confident admit vs. discharge and patient disposition decisions. TriVerity is the first FDA-cleared molecular diagnostic that provides both diagnosis and prognosis for suspected infection or sepsis patients — enabling clinicians to move beyond "is this sepsis?" to "what is driving this illness and what should we do next?"
A single, cost-effective, front-end test that changes patient disposition decisions early — reducing serial and redundant downstream testing while elevating the lab's role in acute infection and sepsis patient care. <1 min hands-on time, room-temperature storage, LIS connectivity.
Objective bacterial, viral, and severity scores that support SEP-1 compliance documentation and provide defensible, biologically grounded evidence for payer audit defense — including the ability to support stepping away from sepsis bundles when alerts are false alarms.
TriVerity represents a new capability, not a traditional diagnostic. It's a specialty diagnostic that aids decision-making at the very front end of care, supporting physician judgment rather than replacing it. Improvements in patient disposition and ED throughput flow directly to operational and financial performance.
Fill out the form and a member of our team will reach out within one business day.
Please fill the form below
© Copyright 2026, Inflammatix, Inc. All Rights Reserved | Terms & Conditions | Privacy & Cookies Statement
Inflammatix, TriVerity, Myrna, RespVerity, and BacVerity are trademarks of Inflammatix, Inc.
